Oncology

Metastatic Breast Cancer

Expert Roundtables Podcast: Treating Patients With HR+/HER2- Metastatic Breast Cancer at Initial Diagnosis

expert roundtables by Joanne Mortimer, MD, FACP, FASCO; David Rimm, MD, PhD; Sagar D. Sardesai, MBBS

Overview

Advances in endocrine therapy and CDK4/6 inhibitors are reshaping first-line treatment for patients with HR+/HER2- metastatic breast cancer. Join expert panelists Joanne Mortimer, MD, FACP, FASCO, David Rimm, MD, PhD, and Sagar D. Sardesai, MBBS, as they discuss biomarker insights and evolving treatment strategies for newly diagnosed HR+/HER2- metastatic breast cancer.

References

Allison KH, Hammond MEH, Dowsett M, et al. Estrogen and progesterone receptor testing in breast cancer: ASCO/CAP guideline update. J Clin Oncol. 2020;38(12):1346-1366. doi:10.1200/JCO.19.02309

Goetz MP, Toi M, Huober J, et al. Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3. Ann Oncol. 2024;35(8):718-727. Published correction appears in Ann Oncol. 2025;36(12):1556.

Hortobagyi GN, Stemmer SM, Burris HA, et al. Overall survival with ribociclib plus letrozole in advanced breast cancer. N Engl J Med. 2022;386(10):942-950. doi:10.1056/NEJMoa2114663

Jhaveri K, O’Shaughnessy J, Fasching PA, et al. Matching-adjusted indirect comparison of PFS and OS comparing ribociclib plus letrozole versus palbociclib plus letrozole as first-line treatment of HR+/HER2- advanced breast cancer. Ther Adv Med Oncol. 2023;15:17588359231216095. doi:10.1177/17588359231216095

Lu YS, Im SA, Colleoni M, et al. Updated overall survival of ribociclib plus endocrine therapy versus endocrine therapy alone in pre- and perimenopausal patients with HR+/HER2- advanced breast cancer in MONALEESA-7: a phase III randomized clinical trial. Clin Cancer Res. 2022;28(5):851-859. doi:10.1158/1078-0432.CCR-21-3032

Neven P, Fasching PA, Chia S, et al. Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2- advanced breast cancer receiving first-line ribociclib plus fulvestrant. Breast Cancer Res. 2023;25(1):103. doi:10.1186/s13058-023-01701-9

Orlandi A. Should CDK4/6 inhibitors replace chemotherapy in HR+/HER2- metastatic breast cancer with visceral crisis? Evaluating the emerging evidence. Discov Oncol. 2025;16(1):982. doi:10.1007/s12672-025-02699-6

Rios-Hoyo A, Shan NL, Karn PL, Pusztai L. Clinical implications of breast cancer intrinsic subtypes. Adv Exp Med Biol. 2025;1464:435-448. doi:10.1007/978-3-031-70875-6_21

Profile

Joanne Mortimer, MD, FACP, FASCO

Baum Family Professor in Women’s Cancers
Associate Director for Cancer Research Training and Education Coordination
Vice Chair and Professor
Department of Medical Oncology and Therapeutics Research
Comprehensive Cancer Center
City of Hope
Duarte, CA

Profile

David Rimm, MD, PhD

Anthony N. Brady Professor of Pathology
Departments of Pathology and Medicine (Medical Oncology)
Director, Yale Pathology Tissue Services
Director, Lab for Quantitative Diagnostics in Anatomic Pathology
Yale School of Medicine
New Haven, CT

Profile

Sagar D. Sardesai, MBBS

Associate Professor
Division of Medical Oncology, Department of Internal Medicine
Co-Medical Director, High-Risk Breast Cancer Program
Stefanie Spielman Comprehensive Breast Center
The Ohio State University Comprehensive Cancer Center – James
Columbus, OH